‘Ozempic drugs’ reduce obesity-associated cancer risk by up to 65%
The popular class of antidiabetic and weight loss drugs known as GLP-1RAs, which includes Ozempic and Wegovy, has been found to significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetics,